Connext

Executive Summary

Connext is a South Korean biotechnology company developing advanced drug delivery technologies for small molecule therapeutics. Its platform addresses key limitations such as poor solubility, low bioavailability, and lack of tissue specificity, with initial applications in oncology and inflammatory diseases. The company is in the preclinical stage and employs 50-200 people. By leveraging its proprietary delivery platform, Connext aims to improve the therapeutic index of existing drugs and enable new chemical entities that were previously undeliverable. The company's focus on high unmet medical needs positions it as a potential partner for pharmaceutical firms seeking to optimize their pipelines. Despite limited public information, Connext's technology could offer significant advantages in drug targeting and patient outcomes if successfully validated.

Upcoming Catalysts (preview)

• Q3 2026Announcement of lead candidate selection for IND-enabling studies70% success
• H2 2026Partnership or licensing deal with a major pharma company for delivery platform40% success
• Q2 2026Publication of preclinical efficacy data in a peer-reviewed journal or conference60% success